Since the completion of the human genome project, it has become clear that characterization of the human proteome is indispensable to our understanding of the biological function and processes of proteins, both in a normal as well as a pathological state. Recently, we, as well as others, have begun to identify proteins that are unique to certain brain regions in order to characterize proteins that may qualitatively change under pathological conditions [1] [2] [3] . For example, proteomic analysis of human frontal cortex that is typically involved in cognitive function and geriatric dementia (using a platform of biochemical fractionation, multi-dimensional LC separation, and a MALDI-TOF/TOF mass spectrometer) identified over 800 proteins, of which several were found to be associated with neurodegenerative disease [1] . Furthermore, examination of the human temporal lobe, a region often involved in epilepsy (using 2-DE separation with MALDI-TOF/TOF [4] as well as a shotgun proteomics approach that utilized strong cation exchange (SCX), RP-LC and 3-D ion trap mass spectrometry [5] ) has identified several hundred proteins, including many linked to epilepsy.
The focus of this dataset paper is the midbrain whose degeneration is linked to multiple movement disorders, including Parkinson's disease (PD), multiple system atrophy, and progressive supranuclear palsy. The human midbrain is composed of several different regions, including the superior and inferior colliculi, red nucleus, substantia nigra pars reticulata, ventral tegmental area (VTA), and substantina nigra pars compacta (SNpc). It is the degeneration of dopaminecontaining neurons in the SNpc that underlies the motor deficits that characterize most movement disorders [6] . In an earlier study of human midbrain we utilized isotope coded affinity tag (ICAT) labeling of mitochondrial-enriched proteins from the SNpc of human PD and control brains, followed by analysis with linear ion trap MS (LTQ) [7] . Comparison of the protein profiles in the SNpc of PD patients with those of age-matched controls identified 842 proteins, of which 119 proteins displayed changes in relative abundance in the diseased tissue vs. controls [7] . These data are a much larger representation of the SNpc proteome than has been previously demonstrated in other studies. For example, examination of SNpc of human PD and control samples through 2-DE identified 44 proteins, of which nine showed changes in expression between control and disease brains [8] .
As a part of an ongoing effort to further characterize and understand the human midbrain proteome as well as identify alterations in protein expression levels in a normal and pathological state, we have recently compared the proteome of the SNpc with another midbrain region, the VTA that is much less sensitive to neurodegeneration in PD. While proteins displaying quantitative changes are being evaluated extensively (and will be published separately), the results on protein identification in the midbrain is reported here, along with proteins identified previously by us [7] after standardization of the data processing. We hope that making these data available to other investigators in the field can facilitate the process of characterization of the human midbrain, comprehensively. To make our dataset even more user-friendly, we will make it publicly accessible on our website as well as the PRIDE database managed by the European Bioinformatics Institute (EBI). Finally, we hope that this dataset will contribute to the current initiatives that are supported by the National Institutes of Health (Brain Molecular Anatomy project: http://trans.nih.gov/bmap/) as well as the Human Proteome Organization (www.hupo. org).
Technical details are provided for three major aspects of the investigation: (i) Sample preparation: Samples from SNpc and VTA of human midbrain were obtained at autopsy according to protocols approved by the University of Washington School of Medicine, Mayo Clinic in Florida, University of Michigan, and Emory University. The average age of the subjects was 76 years old and postmortem interval was less than 12 h. All control subjects (four males and one female; average age: 82 years) were individuals who were not diagnosed with a neurological disease and whose neuropathological examination revealed age-related changes only. All PD patients (five males of an average age of 70 years) had been clinically diagnosed with an extrapyramidal movement disorder or dementia, and their final diagnoses were established by neuropathological examination according to established criteria [9, 10] . Four groups of samples were analyzed: Control VTA (n = 5), Control SNpc (n = 5), PD VTA (n = 5), and PD SNpc (n = 5).
Frozen samples were rapidly thawed in ice-cold homogenization buffer (0.32 M sucrose, 20 mM HEPES, pH 7.5, 1 mM PMSF, phosphatase inhibitors (0.2 mM Na 3 VO 4 and 1 mM NaF) and protease inhibitor cocktail from Sigma, St. Louis, MO), and then disrupted with a glass-Teflon homogenizer (Wheaton, Millville, NJ) by ten gentle up and down strokes. The protein concentrations of the homogenates were determined using a Pierce BCA Protein Assay kit (Rockford, IL). Equal amount of proteins from five individual samples in each group were combined together. Cytosolic, mitochondrial and nuclear fractions of SNpc were prepared as previously described [1] . Fractionation of tissue was not designed to achieve pure sub-cellular organelles, as this is not practically possible for frozen human brain. Rather, this procedure was instituted for deeper probing of the human proteome.
(ii) Protein identification and quantification: For proteins in each of the enriched fractions in the four groups, i.e. control VTA, control SNpc, PD VTA, and PD SNpc, this was achieved using the iTRAQ labeling technique that is routinely utilized in our lab [11] . In this study, for each enriched fraction, 100 mg of proteins from each group were tryptically digested in parallel and then labeled with iTRAQ reagents (Applied Biosystem, Foster City, CA) according to the manufacture's protocol. The labeled digests from the four groups were combined together and further separated into nine fractions using an offline SCX PolySulfoethyl ATM column (200 mm62.1 mm id, 5 micron, 300 Å, Poly LC, Columbia, MD). Of note again, results related to quantitative changes among different regions and/or disease vs. controls will be reported separately.
Each SCX fraction was collected and further separated by RP nanocapillary LC (LC Packing/Dionex, Sunnyvale, CA). The mass spectrometric analysis was carried out using a MALDI-TOF/TOF instrument (4700 Proteomics Analyzer, Applied Biosystems) with reflector positive ion mode and each fraction was analyzed in triplicate. Spectral results were searched against the International Protein Index (IPI) human protein database (version 3.18) from the EBI using the GPS software (version 3.6, Applied Biosystems) running MASCOT search algorithm (version 2.0, Matrix Science, Boston, MA) for peptide and protein identification. All proteins identified by a decoy database (less than 2% of total proteins) were eliminated from the list of proteins reported.
It should be noted that the data related to ICAT and LTQ analysis of SNpc has been reported previously as an appendix associated with a biology paper [7] . A few key elements are repeated here for the readers' reference and standardization of the dataset. Briefly, proteins were identified in the SNpc of control and PD patients using the ICAT labeling technique, initially described by Gygi et al., [12] and routinely used in our lab [1, 3, 13] . For the LTQ platform, peptides were separated and analyzed on an LTQ work station (Thermo Electron, San Jose, CA) using automated, on-line 2-D LC separation followed by nanoelectrospray LC/MS [14] . Proteins from the mixture were later identified automatically using the computer program SEQUEST, which searched the MS/MS spectra against the human IPI database (version 2.33 in initial publication, but reprocessed with version 3.18) database [3, 13] . Potential peptides and proteins were further analyzed with two newly developed computer software programs, PeptideProphet and ProteinProphet based on statistical models [15] . The list of proteins filtered by ProteinProphet typically has very little overlap (less than 1%) with that searched with a decoy database [16] .
(iii) Bioinformatics: The Gene Ontology (GO) analysis was carried out at the Bioinformatics and Biostatistics Facility Core of the University of Washington. All proteins identified were analyzed by GO for protein categorization [17] . Briefly, queries using the IPI values were submitted to the EMBL-EBI IPI database using the Bioconductor [18] software package. Bioconductor commands were used to construct and send dbfetch queries to the IPI database via a URL, for example, http://www.ebi.ac.uk/cgi-bin/dbfetch?db=IPI$id= IPI00298853. These IPI query results were further processed in Bioconductor to construct a master table containing IPIs, Entrez Gene IDs, Gene Symbols, and Gene Descriptions. The Entrez Gene IDs were used in conjunction with the Bioconductor biomart package [19] to query the Ensembl BioMart database for the GO IDs as well as GO categories of the three GOs (Biological Process, Molecular Function, Cellular Component). Because any Entrez Gene ID can occur in more than one GO category, the calculation of the numbers of proteins in selected GO categories, whether cellular component or biological process, was done on a priority basis, meaning that a gene/protein was removed from the master table after it was classified so that multiple counting of the gene/proteins was avoided.
As mentioned previously, the proteins identified in the SNpc in our investigations are the most extensive thus far. A few key technical and biological issues unique to this dataset are discussed further as the following:
(i) Protein identification and GO analysis: All current MS-based proteomics is biased towards identification of proteins of high abundance [20] thus, it is critical to fractionate tissue homogenates to achieve a deeper analysis of the cellular proteome. Moreover, through this approach, it is more likely to identify the proteins whose total cellular levels remain the same but relative levels in specific cellular compartments change during processes. For example, in our previous ICAT analysis of PD SNpc versus control SNpc, mortalin was found to be decreased in mitochondrial but not cytosolic fractions, a fact further validated by alternative means [7] . Our current study led to the identification of 951 proteins; of those, 399 non-redundant proteins were identified with two or more peptides. The number of non-redundant proteins identified with two or more peptides was 313, 114, and 170 for cytosolic, mitochondrial, and nuclear fractions, respectively (a total of 399 after removing redundant proteins). A second set of proteins was identified using a multidimensional separation strategy in combination with an ESI based ion trap mass spectrometer [7, 21] . Using this approach, 1049 proteins were identified by at least two peptides. It should be noted that previous analysis of this same dataset yielded 842 proteins identified by two or more peptides. This discrepancy in the number of proteins identified can be attributed to the rapid progression of the proteomics field and the updating of the protein database that was originally used. Indeed, our previous investigation has indicated that a significant number of proteins are altered when an identical MS data was searched against two different versions of the IPI database [11] .
When MALDI-TOF/TOF protein identification was combined with the LTQ study [7] a total of 1263 non-redundant proteins were identified in the SNpc, which represents the most extensive characterization of the human midbrain to date. Notably, 14 proteins identified previously by a single peptide were seen in the current study with more than two peptides. Conversely, 87 proteins identified in the current study by a single peptide were revealed in the previous investigation by more than two peptides. Nonetheless, to comply with the general rule of proteomic data depository, only proteins identified by more than two peptides in at least one study are reported here. A complete list of the proteins can be found in Supporting Information Table 1 .
SNpc proteins identified by more than two peptides in our study were classified in accordance with their distribution into cellular components and biological processes based on GO analysis and annotations (Supporting Information Fig. 1 ). Categorization of proteins provides a starting point, from which a more in-depth investigation of individual proteins that show potential involvement in PD can be undertaken. The major cellular components of the proteins identified fall into several categories, including mitochondria, membrane and endoplasmic reticulum/lysosome, and nuclear (Supporting Information Fig. 1A) . The main biological functions of the proteins identified in the SNpc include oxidative stress processes, regulation of cytoskeletal organization, as well as participation in cell-cell communication and signaling (Supporting Information Fig. 1B) . A significant portion of proteins have various other functions that collectively fall into a category denoted as "others". With the advance of bioinformatics and proteomics technology, it is hoped that a complete characterization of the midbrain proteome will be achieved in the years to come.
(ii) Comparison of the SNpc proteome with other human brain regions and CSF as well as mouse midbrain: Of the 1263 proteins identified in midbrain, 534 have been reported previously in the temporal cortex [24] and 350 in the frontal cortex [1] . The overlap of the proteins identified in each of the proteomes is demonstrated in Fig. 1A and B, respectively. We have also compared our current SNpc dataset with a previous proteomic study that utilized 2-DE and MALDI-TOF-MS to identify 44 proteins in human SNpc [8] . Of these 44 proteins, over 75% of them were also identified in our study, providing evidence for the validity of our results. In addition, comparison of proteins recently identified by our lab in a proteomic study of mouse midbrain determined overlap between numerous proteins found in both human SNpc and mouse midbrain [3] . Examples of some of these proteins include, HSPs, 14-3-3, thioredoxin, glutathione S-transferase, and ubiquitin carboxy-terminal hydrolase L1 (UCHL-1). These data provide further evidence for the utility of using mice as a reliable model of PD. On the other hand, a significant portion of proteins (over 99%) identified in human SNpc were not identified in a mouse genomic comparison between the SNpc and VTA [23] emphasizing again that it is imperative to investigate the human CNS proteome (ideally human) directly.
Finally, we compared the proteins identified in the midbrain with those in human cerebrospinal fluid (CSF). CSF is easily accessible and the proteins present in it could be used as biomarkers for neurodegenerative diseases. Furthermore, CSF is a viable source for biomarker discovery because of its proximity to the site of pathology and because it reflects the metabolic state of the brain under varying conditions that effect protein concentrations and patterns in CSF considerably. By comparing the previously identified CSF proteome (a total of 2556 proteins) [2, 11] with that of the SNpc identified in our present study, 198 proteins were found to be shared by the SNpc and CSF proteomes (Fig. 1C) . Many of these shared proteins, e.g. calmodulin, g-enolase, and myelin basic protein are known to be involved in a variety of CNS functions. While these data represent the most current evaluation of the human SNpc available, we realize that the dynamic and continually progressing nature of proteomic technology may further validate or abrogate these findings.
(iii) Discussion of the proteins identified in the dataset: Among the proteins identified in the SNpc tissue, many of them are functionally or structurally involved in neurodegeneration. Further characterization of these proteins will facilitate a more complete understanding of the pathogenesis of various movement disorders. Proteins that are well known to be critical to movement disorders are listed in Supporting Information Table 2 . A significant number of these proteins are involved in the process of mitochondrial function, oxidative stress, protein degradation, and neuroinflammation, processes that have been clearly indicated to be important to neurodegenerative diseases, including PD (e.g. DJ-1, glutathione S-transferase omega1, manganese superoxide dismutase, and UCHL-1). These proteins have been discussed extensively in the literature. Additionally, as one of the most important advantages of nonbiased proteomics centers on discovering novel proteins that are yet to be determined to be critical to a particular disease or disease state, we have decided to focus the remainder of the discussion on a subset of proteins that have not been related to PD pathogenesis thus far, although investigations in other fields appear to suggest their roles in neural functions.
Calbindin: Calbindin D28K protein is a calcium binding protein [24] involved in the regulation of intracellular calcium [25] . Calbindin is expressed in dopamine neurons of the dorsal tier of the SNpc that project to the limbic region of the telencephalon and cerebral cortex [26] . In contrast, dopamine neurons from the ventral tiers of the SNpc do not contain calbindin and project to the dorsolateral motor putamen [27] . Interestingly, dopamine neurons located in the VTA also express calbindin [28] yet seem to be less vulnerable to PD than dopamine neurons in the SNpc [29] . Furthermore, Calbindin does not appear to demonstrate a neuroprotective role [30] which suggests that other cellular characteristics are involved in mediating the differential vulnerability of dopamine neurons in the VTA and SNpc.
Calmodulin: Calmodulin is a calcium binding protein that binds and modulates several different cellular processes, including inflammation, metabolism, and apoptosis. Our study identified six peptides associated with calmodulin. Of these, two peptides (91-106, 127-148) cover the calciumbinding regions. A recent study showed that calmodulin binds to a-synuclein in a calcium dependent-manner and accelerates a-synuclein fibrillation [31] which has been demonstrated to be a major factor in the pathogenesis of PD. In addition, oxidative stress and mitochondrial dysfunction have been suggested to be involved in the pathogenesis of neurodegenerative diseases, and calmodulin has been linked to both these processes [32] . Finally, a comparative proteomic analysis of striatum from rats exposed to 6-hydroxy-dopamine identified calmodulin as a protein that underwent a change in expression in rats treated with 6-hydroxy-dopamine, compared with control [33] .
Cofilin: This protein belongs to the protein family of ADF/cofilins [34] and is an important regulator of actin, a key component of microtubules [35] . Disruption of microtubules and subsequent axonal transport could have detrimental effects on numerous cellular processes integral to the well-being of the cell. Cofilin has been implicated initially in Alzheimer's disease [36] and it is suggested that neurodegenerative stimuli can activate ADF/cofilin by dephosphorylation, causing the formation of bars which can impair axonal transport along the microtubules, inhibiting neurite function [37] . There is also data showing that 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) treated mice demonstrate changes in the expression of the cytoskeletal genes, including cofilin [38] . Furthermore, parkin, a protein that has been implicated in inherited forms of PD, may interact with LIM kinase-1 and suppress the phosphorylation of cofilin [39] .
14-3-3: 14-3-3 proteins, a family of chaperones that participate in many signaling pathways, are abundant in the brain. In this study, six different isoforms of 14-3-3 protein were identified in the SNpc, including beta/alpha, epsilon, eta, gamma, theta, and zeta/delta. There is evidence suggesting that 14-3-3 proteins may play a central role in PD pathogenesis [40] as it has been shown by immunochemical studies to colocalize with Lewy bodies [41] . In addition, it has been shown that one family member, 14-3-3 eta specifically interacts with parkin and inhibits its ubiquitin ligase activity, which could impede proteasomal degradation of damaged or misfolded proteins in the cell [42] .
Stathmin: Stathmin is a cytosolic phosphoprotein, abundantly expressed in human brain, playing a role in adult neurogenesis [43] . Stathmin regulates microtubule dynamics [44] and by way of this function it has been suggested by in vitro studies that when overexpressed it could lead to Golgi fragmentation -a process that links stathmin to amyotrophic lateral sclerosis [45] . In addition, stathmin has been associated with Alzheimer's disease and Down's syndrome [46] therefore it could have a role in other neurodegenerative diseases such as PD for which Golgi fragmentation could be a contributing factor in the pathogenesis of neuronal degeneration [47] . Interestingly, a recent study demonstrated Golgi fragmentation in the SNpc of PD patients exhibiting asynuclein positive inclusions [48] .
g-Synuclein: One of the three members of the human synuclein family, including a, b-synuclein, g-synuclein shows 60% similarity with a-synuclein at the amino acid sequence level [49] and is expressed throughout the brain, particularly in the substantia nigra [50] . In contrast to asynuclein, which has been extensively demonstrated to be involved in the pathogenesis of PD, the role of g-synuclein in PD is still disputable. Although studies have demonstrated a lack of specific polymorphisms in the g-synuclein gene, several studies have shown potential aggregations of g-synuclein in neuronal structures [51] . More recently, it has been shown that g-synuclein is able to inhibit a-synuclein fibrillation, a potentially imperative step in a-synuclein-mediated PD pathology [52] .
In summary, our work provides an inventory of proteins that are linked to neurodegenerative processes. The expressed proteins need to be validated and more thoroughly characterized to elucidate their function. It is important to recognize that the SNpc is not a homogeneous structure. In primates, the dopaminergic SNpc neurons are interdigitated with GABAergic substantia nigra pars reticulata neurons. Within the SNpc, some groups of dopaminergic neurons are more affected than others by whatever processes cause neurodegeneration in PD [53] . In the future, more fine grained analyses will be needed to assess protein changes in subpopulations of SNpc neurons. Given the complexity of proteomic research and the limited access to brain tissue from patients and healthy individuals this preliminary protein database of the human SNpc could be the first step towards early diagnosis and development of therapeutic targets. Additionally, proteins present in both tissue and CSF may provide tissue specific markers for PD diagnosis and progression. 
